The purpose of this investigation was to describe the course of IgM, IgA and IgG antibody titers against SARS-CoV-2 over more than 6 months after infection in a well-characterized cohort of front-line healthcare workers with mild to moderate COVID-19 and to explore clinical parameters and infection-related symptoms that might be associated with the magnitude of the humoral response to SARS-CoV-2. This evidence concerns the gene CD79A and COVID-19.